CHRM1 and Alzheimer disease: Notably, MK‐7622 did not improve cognition as adjunctive therapy with AChEIs in patients with AD.30 ACh release is spatiotemporally controlled in tissues, and an appropriate coordinated cholinergic system activation in the brain would be required for cognitive performance.56, 57 Unlike M1R agonists, M1R PAMs are expected to boost the action of ACh and maintain its spatiotemporal characteristics.